74
Views
0
CrossRef citations to date
0
Altmetric
Review

Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals

, , , , , , & show all
Received 11 Apr 2024, Accepted 17 May 2024, Published online: 27 May 2024
 

ABSTRACT

Introduction

With the introduction of highly effective and safe therapies with next-generation direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection remains the only treatable chronic infectious disease.

Areas covered

The review aims to provide an overview of the therapy revolution with a description of specific DAAs, their mechanisms of action, a summary of the safety and efficacy of specific regimens, and a discussion of populations requiring special therapeutic approaches.

Expert Opinion

DAAs are highly effective, safe, and easy to use. However, challenges such as access to health services and loss of patients from the cascade of care, especially in groups disproportionately affected by HCV infection, such as substance abusers, make it difficult to achieve the WHO’s goal of HCV elimination. The proposed strategy to combat these difficulties involves a one-step approach to diagnosing and treating the infection, the availability of long-lasting forms of medication, and the development of an effective vaccine. The aforementioned opportunities are all the more important as the world is facing an opioid epidemic that is translating into an increase in HCV prevalence. This phenomenon is of greatest concern in women of childbearing age and in those already pregnant due to treatment limitations.

Plain Language Summary

Hepatitis C virus (HCV) is an insidious pathogen. Most people infected with HCV will develop chronic infections that may not give any symptoms for years or decades but eventually lead to liver disease and liver cancer. It is essential to diagnose infected individuals as soon as possible and start the treatment to increase the elimination of the virus from the organism and prevent harmful long-term effects.

Fortunately, these goals are possible nowadays, and this is due to a remarkable example of translational research at work. The discovery of the virus in 1989 (for which Harvey J. Alter, Michael Houghton, and Charles M. Rice received the Nobel Prize in 2020) was followed by the rapid development of diagnostic tests and later by the introduction of the first interferon therapies, which had numerous shortcomings. The revolution started in 2011 when the first oral drugs that act directly on HCV (direct-acting antivirals, DAAs) were registered. Another giant leap for HCV treatment was made in 2018 when the combinations of DAAs that act on different HCV genotypes were introduced.

In this paper, we review in detail the DAAs used to treat HCV infection and explain different combinations in which they can be used while showing their favorable safety profile, short-term and convenient treatment regimen, and impressive effectiveness in clearing HCV infection. Although we believe eliminating HCV is eventually reachable, we also argue that there is room for improvement. HCV testing and DAAs availability must improve in selected groups, including people without health insurance, prisoners, and drug addicts. There are still people living with chronic HCV infection without knowing it. Their identification and start of effective treatment is equal to savings in future medical care related to liver disease and cancer, not to mention benefits from the individual health perspective. In addition, and in line with a popular phrase that prevention is better than cure, it is reasonable to pursue the development of the HCV vaccine, which is currently unavailable. The last word on managing the health burden caused by this pathogen is yet to be said.

Article highlights

  • Current treatment of hepatitis C with orally administered direct-acting antivirals is considered highly effective and provides a good safety profile compared to previous IFN-based regimens.

  • To further improve the treatment, the focus should remain on the underserved groups, such as those without health insurance, incarcerated, and struggling with substance abuse.

  • The goal for the future involves such areas as the possibility of initiating treatment during pregnancy and the development of an effective vaccine.

Abbreviation

ART=

Antiretroviral therapy

ASV=

Asunaprevir

BOC=

Boceprevir

BCRP=

Breast cancer resistance protein

CAS=

Chemical Abstracts Service Registry Number

CP=

Child-Pugh Classification

CHC=

Chronic hepatitis C

CKD=

Chronic kidney disease

CYP=

cytochrome P450

CYP2B6=

cytochrome P4502B6

CYP2C8=

cytochrome P4502C8

CYP3A4=

cytochrome P4503A4

DCV=

Daclatasvir

DSV=

Dasabuvir

DAA=

Direct-acting antiviral

DDIs=

Drug-drug interactions

EBR=

Elbasvir

ESRD=

End-stage renal disease

E1=

Envelope E1 glycoprotein

E2=

Envelope E2 glycoprotein

GT=

Genotype

GECCO=

German Hepatitis C Cohort

GLE=

Glecaprevir

GZR=

Grazoprevir

HBV=

Hepatitis B

HBsAg=

Hepatitis B virus surface antigen

HCV=

Hepatitis C virus

CORE=

Hepatitis C virus core protein

p7=

Hepatitis C virus viroporin p7

HCC=

Hepatocellular carcinoma

HIV=

Human immunodeficiency virus

IFN=

Interferon

LDV=

Ledipasvir

MSM=

Men Who Have Sex With Men

mITT=

Modified intention-to-treat

NANBH=

Non-a, Non- B hepatitis

NS2=

Non-structural 2 protein

NS3=

Non-structural 3 protein

NS3/4A=

Non-structural 3/4A protein

NS4A=

Non-structural 4A protein

NS4B=

Non-structural 4B protein

NS5A=

Non-structural 5A protein

NS5B=

Non-structural 5B protein

NA=

Nucleoside/nucleotide analogue

OBV=

Ombitasvir

OATP1B=

Organic anion transporting polypeptide 1B

PTV=

Paritaprevir

Peg=

Pegylated

PWID=

People who inject drugs

PY=

Person-years

P-gp=

P-glycoprotein

PIB=

Pibrentasvir

PIs=

Protease inhibitors

HBVr=

Reactivation of HBV

RWE=

Real-world evidence

RAS=

Resistance-associated substitutions

RBV=

Ribavirin

RNA=

Ribonucleic acid

PTV/r=

Ritonavir-boosted paritaprevir

SMV=

Simeprevir

SOF=

Sofosbuvir

SVR=

Sustained virological response

TVR=

Telaprevir

TDF=

Tenofovir disoproxil

AASLD=

The American Association for the Study of Liver Disease

EASL=

The European Association for the Study of the Liver

EMA=

The European Medicines Agency

FDA=

The Food and Drug Administration

T-ex=

Treatment-experienced

T-naïve=

Treatment-naïve

UTR=

Untranslated region

VEL=

Velpatasvir

VOX=

Voxilaprevir

WHO=

World Health Organization

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14656566.2024.2358139.

Additional information

Funding

This paper was not funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.